NCT00430066

Effects of Imatinib Mesylate in Polycythemia Vera

Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Niguarda Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single agent, in inducing a haematological response in Polycythemia Vera. The patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.

Detailed description

Hematocrit \<45% in men or \<42% in women at 1°evaluation within 6 months In case of complete or partial responsiveness, experimental treatment will be continued until 12 months In case of disease progression or treatment failure, experimental drug will be withdrawn and patient will be out of the study

Conditions

• Polycythemia Vera

Interventions

Type	Name	Description
DRUG	Imatinib Mesylate	400 mg/die for 6 months

Timeline

• Start date: 2007-02-01
• Primary completion: 2009-11-01
• Completion: 2012-09-01
• First posted: 2007-02-01
• Last updated: 2014-10-08